GROV Quote, Financials, Valuation and Earnings

Hims & Hers Health has a net margin of -2.77% compared to Grove Collaborative Holdings's net margin of 18.82%. Grove Collaborative Holdings's return on equity of -125.41% beat Hims & Hers Health's return on equity of 27.83%.

Grove Collaborative Holdings has a consensus price target of --, signalling upside risk potential of 81.16%. On the other hand Hims & Hers Health has an analysts' consensus of $24.90 which suggests that it could fall by -12.59%. Given that Grove Collaborative Holdings has higher upside potential than Hims & Hers Health, analysts believe Grove Collaborative Holdings is more attractive than Hims & Hers Health.

Grove Collaborative Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hims & Hers Health has a beta of 1.247, suggesting its more volatile than the S&P 500 by 24.726%.

Grove Collaborative Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hims & Hers Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grove Collaborative Holdings pays -- of its earnings as a dividend. Hims & Hers Health pays out -- of its earnings as a dividend.

Grove Collaborative Holdings quarterly revenues are $48.3M, which are smaller than Hims & Hers Health quarterly revenues of $401.6M. Grove Collaborative Holdings's net income of -$1.3M is lower than Hims & Hers Health's net income of $75.6M. Notably, Grove Collaborative Holdings's price-to-earnings ratio is -- while Hims & Hers Health's PE ratio is 64.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grove Collaborative Holdings is 0.24x versus 5.22x for Hims & Hers Health. Usually stocks with elevated PS ratios are considered overvalued.

Kenvue has a net margin of -2.77% compared to Grove Collaborative Holdings's net margin of 9.82%. Grove Collaborative Holdings's return on equity of -125.41% beat Kenvue's return on equity of 9.94%.

Grove Collaborative Holdings has a consensus price target of --, signalling upside risk potential of 81.16%. On the other hand Kenvue has an analysts' consensus of $22.44 which suggests that it could grow by 13.43%. Given that Grove Collaborative Holdings has higher upside potential than Kenvue, analysts believe Grove Collaborative Holdings is more attractive than Kenvue.

Grove Collaborative Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kenvue has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Grove Collaborative Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kenvue offers a yield of 3.73% to investors and pays a quarterly dividend of $0.21 per share. Grove Collaborative Holdings pays -- of its earnings as a dividend. Kenvue pays out 874.64% of its earnings as a dividend.

Grove Collaborative Holdings quarterly revenues are $48.3M, which are smaller than Kenvue quarterly revenues of $3.9B. Grove Collaborative Holdings's net income of -$1.3M is lower than Kenvue's net income of $383M. Notably, Grove Collaborative Holdings's price-to-earnings ratio is -- while Kenvue's PE ratio is 39.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grove Collaborative Holdings is 0.24x versus 2.70x for Kenvue. Usually stocks with elevated PS ratios are considered overvalued.

The Beauty Health has a net margin of -2.77% compared to Grove Collaborative Holdings's net margin of -23.21%. Grove Collaborative Holdings's return on equity of -125.41% beat The Beauty Health's return on equity of -41.24%.

Grove Collaborative Holdings has a consensus price target of --, signalling upside risk potential of 81.16%. On the other hand The Beauty Health has an analysts' consensus of -- which suggests that it could grow by 9.34%. Given that Grove Collaborative Holdings has higher upside potential than The Beauty Health, analysts believe Grove Collaborative Holdings is more attractive than The Beauty Health.

Grove Collaborative Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Beauty Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Grove Collaborative Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Beauty Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grove Collaborative Holdings pays -- of its earnings as a dividend. The Beauty Health pays out -- of its earnings as a dividend.

Grove Collaborative Holdings quarterly revenues are $48.3M, which are smaller than The Beauty Health quarterly revenues of $78.8M. Grove Collaborative Holdings's net income of -$1.3M is higher than The Beauty Health's net income of -$18.3M. Notably, Grove Collaborative Holdings's price-to-earnings ratio is -- while The Beauty Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grove Collaborative Holdings is 0.24x versus 0.61x for The Beauty Health. Usually stocks with elevated PS ratios are considered overvalued.

Waldencast PLC has a net margin of -2.77% compared to Grove Collaborative Holdings's net margin of --. Grove Collaborative Holdings's return on equity of -125.41% beat Waldencast PLC's return on equity of -9.22%.

Grove Collaborative Holdings has a consensus price target of --, signalling upside risk potential of 81.16%. On the other hand Waldencast PLC has an analysts' consensus of -- which suggests that it could grow by 44.36%. Given that Grove Collaborative Holdings has higher upside potential than Waldencast PLC, analysts believe Grove Collaborative Holdings is more attractive than Waldencast PLC.

Grove Collaborative Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Waldencast PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Grove Collaborative Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Waldencast PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grove Collaborative Holdings pays -- of its earnings as a dividend. Waldencast PLC pays out -- of its earnings as a dividend.

Grove Collaborative Holdings quarterly revenues are $48.3M, which are larger than Waldencast PLC quarterly revenues of --. Grove Collaborative Holdings's net income of -$1.3M is higher than Waldencast PLC's net income of --. Notably, Grove Collaborative Holdings's price-to-earnings ratio is -- while Waldencast PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grove Collaborative Holdings is 0.24x versus 1.68x for Waldencast PLC. Usually stocks with elevated PS ratios are considered overvalued.